Prognostic value of RANK signalling in breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Objectives

To evaluate the prognostic value of osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) of the RANK signalling in patients with breast cancer.

Design

Systematic review and meta-analysis.

Data sources

We searched the PubMed, Embase and Cochrane databases up to October 2024.

Eligibility criteria

Studies of patients with primary breast cancer evaluating OPG, RANK or RANKL expression in relation to survival outcomes were included.

Data extraction and synthesis

Data from eligible studies were extracted, and HRs with 95% CIs for overall survival (OS), metastasis-free survival (MFS) and disease-free survival (DFS) were used to assess prognostic value.

Results

A total of 18 studies, comprising 11 141 pa

SUBMITTER: Li L 

PROVIDER: S-EPMC12606498 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature